Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Shares Issued (2016 - 2025)

Vistagen Therapeutics (VTGN) has disclosed Shares Issued for 14 consecutive years, with $2.3 million as the latest value for Q4 2025.

  • Quarterly Shares Issued rose 109.09% to $2.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $29.4 million through Dec 2025, down 68.92% year-over-year, with the annual reading at $93.5 million for FY2024, N/A changed from the prior year.
  • Shares Issued hit $2.3 million in Q4 2025 for Vistagen Therapeutics, down from $27.9 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $93.4 million in Q1 2024 to a low of -$1.2 million in Q1 2025.
  • Historically, Shares Issued has averaged $9.5 million across 5 years, with a median of $748500.0 in 2024.
  • Biggest five-year swings in Shares Issued: tumbled 102.87% in 2022 and later surged 779900.0% in 2023.
  • Year by year, Shares Issued stood at $2.0 million in 2021, then crashed by 102.87% to -$56100.0 in 2022, then soared by 105.35% to $3000.0 in 2023, then soared by 36566.67% to $1.1 million in 2024, then skyrocketed by 109.09% to $2.3 million in 2025.
  • Business Quant data shows Shares Issued for VTGN at $2.3 million in Q4 2025, $27.9 million in Q3 2025, and $397000.0 in Q2 2025.